MYRIAD GENETICS, INC. Operating Expenses
MYRIAD GENETICS, INC. (MYGN) reported Operating Expenses of $165.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-31
- MYRIAD GENETICS, INC. operating expenses for the quarter ending 2026-06-30 was $165.90M, a 65.51% decline year-over-year.
- MYRIAD GENETICS, INC. operating expenses for the quarter ending 2026-03-31 was $168.30M, a 3.13% increase year-over-year.
- MYRIAD GENETICS, INC. operating expenses for the quarter ending 2025-12-31 was $152.50M, a 19.69% decline year-over-year.
- MYRIAD GENETICS, INC. operating expenses for the quarter ending 2025-09-30 was $167.10M, a 1.59% decline year-over-year.
- MYRIAD GENETICS, INC. operating expenses for fiscal 2025 was $963.80M, a 35.96% increase from fiscal 2024.
- MYRIAD GENETICS, INC. operating expenses for fiscal 2024 was $708.90M, a 8.46% decline from fiscal 2023.
- MYRIAD GENETICS, INC. operating expenses for fiscal 2023 was $774.40M, a 25.51% increase from fiscal 2022.
- MYRIAD GENETICS, INC. operating expenses for fiscal 2022 was $617.00M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $165.90M 10-Q · filed 2026-07-31 | $334.20M 10-Q · filed 2026-07-31 | $486.70M derived: sum of 3 quarters · filed 2026-07-31 | $653.80M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $168.30M 10-Q · filed 2026-05-06 | $320.80M derived: sum of 2 quarters · filed 2026-05-06 | $487.90M derived: sum of 3 quarters · filed 2026-05-06 | $968.90M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $152.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $319.60M derived: sum of 2 quarters · filed 2026-02-24 | $800.60M derived: sum of 3 quarters · filed 2026-07-31 | $963.80M 10-K · filed 2026-02-24 |
| 2025-09-30 | $167.10M 10-Q · filed 2025-11-04 | $648.10M derived: sum of 2 quarters · filed 2026-07-31 | $811.30M 10-Q · filed 2025-11-04 | $1.00B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $481.00M 10-Q · filed 2026-07-31 | $644.20M 10-Q · filed 2026-07-31 | $834.10M derived: sum of 3 quarters · filed 2026-07-31 | $1.00B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $163.20M 10-Q · filed 2026-05-06 | $353.10M derived: sum of 2 quarters · filed 2026-05-06 | $522.90M derived: sum of 3 quarters · filed 2026-05-06 | $706.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $189.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $359.70M derived: sum of 2 quarters · filed 2026-02-24 | $543.30M derived: sum of 3 quarters · filed 2026-02-24 | $708.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | $169.80M 10-Q · filed 2025-11-04 | $353.40M derived: sum of 2 quarters · filed 2025-11-04 | $519.00M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $183.60M 10-Q · filed 2025-08-06 | $349.20M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $165.50M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $774.40M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $617.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |